1. Home
  2. HOOK vs GDC Comparison

HOOK vs GDC Comparison

Compare HOOK & GDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HOOK
  • GDC
  • Stock Information
  • Founded
  • HOOK 2011
  • GDC 2015
  • Country
  • HOOK United States
  • GDC United States
  • Employees
  • HOOK N/A
  • GDC N/A
  • Industry
  • HOOK Biotechnology: Pharmaceutical Preparations
  • GDC Steel/Iron Ore
  • Sector
  • HOOK Health Care
  • GDC Industrials
  • Exchange
  • HOOK Nasdaq
  • GDC Nasdaq
  • Market Cap
  • HOOK 9.3M
  • GDC 29.0M
  • IPO Year
  • HOOK 2019
  • GDC N/A
  • Fundamental
  • Price
  • HOOK $1.25
  • GDC $3.26
  • Analyst Decision
  • HOOK Buy
  • GDC
  • Analyst Count
  • HOOK 4
  • GDC 0
  • Target Price
  • HOOK $10.67
  • GDC N/A
  • AVG Volume (30 Days)
  • HOOK 62.6K
  • GDC 169.0K
  • Earning Date
  • HOOK 08-07-2025
  • GDC 08-13-2025
  • Dividend Yield
  • HOOK N/A
  • GDC N/A
  • EPS Growth
  • HOOK N/A
  • GDC N/A
  • EPS
  • HOOK N/A
  • GDC N/A
  • Revenue
  • HOOK $9,351,000.00
  • GDC N/A
  • Revenue This Year
  • HOOK N/A
  • GDC N/A
  • Revenue Next Year
  • HOOK N/A
  • GDC N/A
  • P/E Ratio
  • HOOK N/A
  • GDC N/A
  • Revenue Growth
  • HOOK N/A
  • GDC N/A
  • 52 Week Low
  • HOOK $0.72
  • GDC $1.03
  • 52 Week High
  • HOOK $6.77
  • GDC $12.18
  • Technical
  • Relative Strength Index (RSI)
  • HOOK 39.11
  • GDC 58.57
  • Support Level
  • HOOK $1.17
  • GDC $2.32
  • Resistance Level
  • HOOK $1.30
  • GDC $3.57
  • Average True Range (ATR)
  • HOOK 0.07
  • GDC 0.35
  • MACD
  • HOOK -0.02
  • GDC 0.07
  • Stochastic Oscillator
  • HOOK 20.98
  • GDC 61.40

About HOOK HOOKIPA Pharma Inc.

HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.

About GDC GD Culture Group Limited

GD Culture Group Ltd focuses its business on two segments mainly through the Company and two subsidiaries. 1) AI-driven digital human creation and customization; 2) Live streaming and e-commerce. The company has relentlessly been focusing on serving its customers and creating value for them through the continual innovation and optimization of its products and services. For the AI-driven digital human creation and customization sector, the Company uses AI algorithms and software to generate realistic 3D or 2D digital human models. AI algorithms and machine learning models are used to simulate human characteristics, such as facial expressions, body movements, and even speech patterns.

Share on Social Networks: